

Resource Summary Report

Generated by T1D on Aug 1, 2026

Bio X Cell

RRID:SCR_004997

Type: Tool

Proper Citation

Bio X Cell (RRID:SCR_004997)

Resource Information

URL: <https://bxccl.com/>

Proper Citation: Bio X Cell (RRID:SCR_004997)

Description: Commercial supplier and developer of in vivo antibodies. Provides antibodies and antibody production services.

Resource Type: commercial organization

Keywords: commercial, antibody, reagent, biomedical, research, new hampshire,

Resource Name: Bio X Cell

Resource ID: SCR_004997

Alternate IDs: SCR_019248, nlx_152318

Record Creation Time: 20220129T080227+0000

Record Last Update: 20260725T190557+0000

Ratings and Alerts

No rating or validation information has been found for Bio X Cell.

No alerts have been found for Bio X Cell.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 4386 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#) .

Gates TJ, et al. (2023) Allogeneic Tumor Cell-Derived Extracellular Vesicles Stimulate CD8 T Cell Response in Colorectal Cancer. *bioRxiv : the preprint server for biology*.

Comunanza V, et al. (2023) Dual VEGFA/BRAF targeting boosts PD-1 blockade in melanoma through GM-CSF-mediated infiltration of M1 macrophages. *Molecular oncology*.

Glasner A, et al. (2023) Conserved transcriptional connectivity of regulatory T cells in the tumor microenvironment informs new combination cancer therapy strategies. *Nature immunology*, 24(6), 1020.

Rodriguez J, et al. (2023) Predictive nonlinear modeling of malignant myelopoiesis and tyrosine kinase inhibitor therapy. *eLife*, 12.

Spiteri AG, et al. (2023) Temporal tracking of microglial and monocyte single-cell transcriptomics in lethal flavivirus infection. *Acta neuropathologica communications*, 11(1), 60.

Sun M, et al. (2023) Circulating Cell-Free DNAs as a Biomarker and Therapeutic Target for Acetaminophen-Induced Liver Injury. *Advanced science (Weinheim, Baden-Wuerttemberg, Germany)*, 10(16), e2206789.

Bhatia V, et al. (2023) Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. *Nature communications*, 14(1), 2041.

Wang Y, et al. (2023) Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy. *Nature communications*, 14(1), 1993.

Mariano NC, et al. (2023) Inducible protein degradation as a strategy to identify Phosphoprotein Phosphatase 6 substrates in RAS-mutant colorectal cancer cells. *bioRxiv : the preprint server for biology*.

Morehead LC, et al. (2023) Increased response to immune checkpoint inhibitors with dietary methionine restriction. *bioRxiv : the preprint server for biology*.

Corria-Osorio J, et al. (2023) Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8+ T cells. *Nature immunology*, 24(5), 869.

Azulay M, et al. (2023) Tumor-targeted superantigens produce curative tumor immunity with induction of memory and demonstrated antigen spreading. *Journal of translational medicine*, 21(1), 222.

Tian P, et al. (2023) Early life gut microbiota sustains liver-resident natural killer cells maturation via the butyrate-IL-18 axis. *Nature communications*, 14(1), 1710.

Solé P, et al. (2023) A T follicular helper cell origin for T regulatory type 1 cells. *Cellular & molecular immunology*, 20(5), 489.

Liu C, et al. (2023) Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer. *Cancer communications (London, England)*, 43(4), 435.

Zhang X, et al. (2023) Antigen-specific memory Th17 cells promote cross-protection against nontypeable *Haemophilus influenzae* after mild influenza A virus infection. *Mucosal immunology*, 16(2), 153.

Chen P, et al. (2023) An IL-12-Based Nanocytokine Safely Potentiates Anticancer Immunity through Spatiotemporal Control of Inflammation to Eradicate Advanced Cold Tumors. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 10(10), e2205139.

In 't Veld AE, et al. (2023) Immunosuppression by hydroxychloroquine: mechanistic proof in in vitro experiments but limited systemic activity in a randomized placebo-controlled clinical pharmacology study. *Immunologic research*, 1.

Cui L, et al. (2023) Innate immune cell activation causes lung fibrosis in a humanized model of long COVID. *Proceedings of the National Academy of Sciences of the United States of America*, 120(10), e2217199120.

Di Nitto C, et al. (2023) An Engineered IFN γ -Antibody Fusion Protein with Improved Tumor-Homing Properties. *Pharmaceutics*, 15(2).